CAS: 1245603-92-2

PF-04937319

PF 04937319 is an investigative ophthalmic drug candidate, which is derived from chemical synthesis. It functions as an inhibitor of the Rho kinase enzyme. The Rho kinase pathway is critical in regulating aqueous humor outflow in the eye, and its inhibition reduces intraocular pressure, a primary risk factor for glaucoma. In detail, PF 04937319 targets the molecular mechanism that modulates actin cytoskeleton dynamics in trabecular meshwork cells. By hindering Rho kinase activity, it leads to relaxation of these cells, enhanced aqueous humor outflow, and subsequently decreases intraocular pressure. The specificity of this mode of action allows for potential enhancements in therapeutic outcomes in patients with open-angle glaucoma or ocular hypertension. Ongoing studies aim to further elucidate its pharmacokinetic profile and long-term tolerability. Its role in eye health is pivotal, given the progressive nature of glaucoma and the limited regenerative capacity of retinal ganglion cells.

PF-04937319 activates glucokinase (EC50=154.4μM) with low hypoglycemia risk, researched for type 2 diabetes treatment.